Effect of esketamine on postoperative quality of recovery in patients undergoing arthroscopic rotator cuff repair: protocol for a prospective, randomized, double-blind study.
Trials December 4, 2024 Qirong Sun, Jiao Luo, Shijia Zhang et al. 1 citation
Early postoperative pain and neurological dysfunction impair recovery after arthroscopic rotator cuff repair. Esketamine, an NMDA receptor antagonist, may reduce opioid use, inflammation, and protect nerves. This single-center, randomized controlled trial will enroll 234 patients undergoing arthroscopic rotator cuff repair, assigning them to general anesthesia with one of two doses of esketamine or saline. The primary outcome is quality of early recovery measured by the QoR-15 scale on postoperative day 1. Secondary outcomes include QoR-15 scores on day 3, remifentanil consumption, vasoactive drug use, cerebral desaturation, pain scores, delirium, and adverse events. The study aims to assess whether esketamine mitigates effects of controlled hypotension on cerebral oxygen saturation and postoperative delirium.